Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma

Shohdy, Kyrillus S.; Villamar, Dario Martin; Cao, Yen; Trieu, Janson; Price, Kristin S.; Nagy, Rebecca J.; Tagawa, Scott T.; Molina, Ana M.; Sternberg, Cora N.; Nanus, David M.; Mosquera, Juan Miguel; Elemento, Olivier; Sonpavde, Guru; Grivas, Petros; Vogelzang, Nicholas J.; Faltas, Bishoy

doi:10.1038/s41416-021-01648-8

Cited by 19 publications

(32 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also evaluated the anticipation period for detecting tumor progression of molecular techniques over conventional imaging techniques. In agreement with other studies [ 37 , 38 ], we demonstrated that ctDNA status could identify BC recurrence with a lower median lead time compared with imaging techniques. Moreover, our previous study [ 24 ] determined that circulating tumor cell (CTC) enumeration was able to detect early tumor progression in MIBC, further supporting the usefulness of liquid biopsy in monitoring MIBC patients after RC.…”

Section: Discussionsupporting

confidence: 93%

“…We showed that patients’ molecular response, understood as plasma ctDNA clearance four months after RC, was associated with better outcomes. Shohdy et al [ 38 ] also demonstrated that ctDNA clearance after adjuvant therapy was associated with longer survival in advanced BC patients, and Magbanua et al [ 39 ] found a similar result in breast cancer patients. Moreover, Yang et al [ 28 ] found that lung cancer patients with negative ctDNA status had better outcomes than those with positive ctDNA status after therapy.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder Cancer

Carrasco

Ingelmo-Torres

Gómez

et al. 2022

IJMS

View full text Add to dashboard Cite

Cell-free DNA (cfDNA) has recently emerged as a real-time biomarker for diagnosis, monitoring and prediction of therapy response in tumoral disease. Here, we evaluated cfDNA as a prognostic biomarker for monitoring muscle-invasive bladder cancer (MIBC) patients at different follow-up time points. Blood samples from 37 MIBC patients who underwent radical cystectomy (RC) were collected at cystectomy and 1, 4, 12 and 24 months later. Plasma cfDNA amount and fragmentation patterns were determined. Four mutations were analyzed in cfDNA to detect circulating tumor DNA (ctDNA) during patient follow-up. During a median follow-up of 36 months, 46% of patients progressed; median time to progression was 10 months. cfDNA levels and ctDNA status four months after RC were identified as independent prognostic biomarkers of tumor progression (HR 5.290; p = 0.033) and cancer-specific survival (HR 4.199; p = 0.038), respectively. Furthermore, ctDNA clearance four months after RC was significantly associated with patients’ clinical outcomes. In conclusion, cfDNA levels and ctDNA status four months after RC have prognostic implications in MIBC patients. In addition, cfDNA monitoring is useful to predict patient outcomes after RC. cfDNA analysis in the clinical setting could greatly improve MIBC patient management.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 97%

Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder Cancer

Carrasco

Ingelmo-Torres

Gómez

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…These data indicate the uncertainty of using ctDNA in PC. In a study, target sequencing of 182 serial ctDNA samples from 53 advanced urothelial cancer patients was performed [ 207 ]. The serial ctDNA data and monitoring the variant allele frequencies was combined with clinical factors.…”

Section: Cell-free Dna In Diagnosismentioning

confidence: 99%

The Role of Cell-Free DNA in Cancer Treatment Decision Making

Telekes

Horváth

2022

Cancers

View full text Add to dashboard Cite

The aim of this review is to evaluate the present status of the use of cell-free DNA and its fraction of circulating tumor DNA (ctDNA) because this year July 2022, an ESMO guideline was published regarding the application of ctDNA in patient care. This review is for clinical oncologists to explain the concept, the terms used, the pros and cons of ctDNA; thus, the technical aspects of the different platforms are not reviewed in detail, but we try to help in navigating the current knowledge in liquid biopsy. Since the validated and adequately sensitive ctDNA assays have utility in identifying actionable mutations to direct targeted therapy, ctDNA may be used for this soon in routine clinical practice and in other different areas as well. The cfDNA fragments can be obtained by liquid biopsy and can be used for diagnosis, prognosis, and selecting among treatment options in cancer patients. A great proportion of cfDNA comes from normal cells of the body or from food uptake. Only a small part (<1%) of it is related to tumors, originating from primary tumors, metastatic sites, or circulating tumor cells (CTCs). Soon the data obtained from ctDNA may routinely be used for finding minimal residual disease, detecting relapse, and determining the sites of metastases. It might also be used for deciding appropriate therapy, and/or emerging resistance to the therapy and the data analysis of ctDNA may be combined with imaging or other markers. However, to achieve this goal, further clinical validations are inevitable. As a result, clinicians should be aware of the limitations of the assays. Of course, several open questions are still under research and because of it cfDNA and ctDNA testing are not part of routine care yet.

show abstract

“…It was found that tumor FGFR3 and PI3KCA mutations were significantly associated with subsequent disease recurrence, and that the expression of genes with multiple hotspot mutations could improve the prognostic monitoring performance of ctDNA [ 133 ]. Sequential ctDNA analysis can monitor dynamic changes in the frequency of genomically altered variant alleles and can predict disease progression and guide precise medication administration in patients with advanced BC [ 134 ]. In a recent retrospective study, ctDNA was found to identify clinically relevant molecular abnormalities, particularly, alterations in the BRCA-1 DNA repair-associated ( BRCA1 ) and Raf-1 proto-oncogene ( RAF1 ) genes appeared to be negatively associated with clinical outcomes [ 134 ].…”

Section: Introductionmentioning

confidence: 99%

“…Sequential ctDNA analysis can monitor dynamic changes in the frequency of genomically altered variant alleles and can predict disease progression and guide precise medication administration in patients with advanced BC [ 134 ]. In a recent retrospective study, ctDNA was found to identify clinically relevant molecular abnormalities, particularly, alterations in the BRCA-1 DNA repair-associated ( BRCA1 ) and Raf-1 proto-oncogene ( RAF1 ) genes appeared to be negatively associated with clinical outcomes [ 134 ].…”

Section: Introductionmentioning

confidence: 99%

Blood-based liquid biopsy: insights into early detection, prediction, and treatment monitoring of bladder cancer

Xin

Shen

et al. 2023

Cell Mol Biol Lett

View full text Add to dashboard Cite

Bladder cancer (BC) is a clinical challenge worldwide with late clinical presentation, poor prognosis, and low survival rates. Traditional cystoscopy and tissue biopsy are routine methods for the diagnosis, prognosis, and monitoring of BC. However, due to the heterogeneity and limitations of tumors, such as aggressiveness, high cost, and limited applicability of longitudinal surveillance, the identification of tumor markers has attracted significant attention in BC. Over the past decade, liquid biopsies (e.g., blood) have proven to be highly efficient methods for the discovery of BC biomarkers. This noninvasive sampling method is used to analyze unique tumor components released into the peripheral circulation and allows serial sampling and longitudinal monitoring of tumor progression. Several liquid biopsy biomarkers are being extensively studied and have shown promising results in clinical applications of BC, including early detection, detection of microscopic residual disease, prediction of recurrence, and response to therapy. Therefore, in this review, we aim to provide an update on various novel blood-based liquid biopsy markers and review the advantages and current limitations of liquid biopsy in BC therapy. The role of blood-based circulating tumor cells, circulating tumor DNA, cell-free RNA, exosomes, metabolomics, and proteomics in diagnosis, prognosis, and treatment monitoring, and their applicability to the personalized management of BC, are highlighted.

show abstract

Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma

Cited by 19 publications

References 36 publications

Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder Cancer

Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder Cancer

The Role of Cell-Free DNA in Cancer Treatment Decision Making

Blood-based liquid biopsy: insights into early detection, prediction, and treatment monitoring of bladder cancer

Contact Info

Product

Resources

About